Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Kintor Pharmaceutical Partners with Fonow Medicine – KT-939 Cosmetic Collaboration Targets China Whitening and Melasma Market

Fineline Cube Mar 13, 2026
Company Deals

APC Group and Youcare Pharmaceutical Forge Strategic Partnership – Global Distribution Alliance Targets China-India Pharma Collaboratio

Fineline Cube Mar 13, 2026
Company Deals

WuXi Biologics Partners with Earendil Labs – Integrated CDMO Services for Bispecific Antibodies and ADCs Targeting Autoimmune and Oncology Indications

Fineline Cube Mar 13, 2026
Company Deals

Everest Medicines Reports Positive Phase IIa Data for VIS-101 – Dual VEGF-A/Ang-2 Inhibitor Shows Best-in-Class Potential in wAMD

Fineline Cube Mar 13, 2026
Company Deals

Luye Pharma Signs Strategic Partnership with Sinopharm – Mimeixin Distribution Deal Targets China’s Severe Pain Market

Fineline Cube Mar 13, 2026
Policy / Regulatory

FDA Streamlines Biosimilar Development – New Guidance Cuts PK Study Costs by 50%, Accelerates Path to Market

Fineline Cube Mar 10, 2026
Company Drug

Sino Biopharm’s TQB3454 Hits Phase III Endpoints in IDH1+ Biliary Tract Cancer – China’s First IDH1 Inhibitor Poised for NDA Filing

Fineline Cube Mar 13, 2026
Company Drug

CMS Launches Opzelura Nationwide – First Topical JAK Inhibitor for Vitiligo Reaches 1,300+ Pharmacies Across 30 Chinese Provinces

Fineline Cube Mar 13, 2026
Company Drug

Takeda’s Obizur Prioritized for Review in Acquired Hemophilia A Treatment

Fineline Cube Jul 1, 2022

The Center for Drug Evaluation (CDE) website indicates that Takeda Pharmaceutical Co., Ltd’s Obizur (susoctocog...

Company Deals

Corestar Biotech Secures Series A Funding for POCT R&D Expansion

Fineline Cube Jun 30, 2022

Shenzhen-based point-of-care testing (POCT) specialist Corestar Biotechnology Co., Ltd has raised “tens of millions” of...

Company Deals

Great Robotics Raises RMB 100M for Surgical Robot Development

Fineline Cube Jun 30, 2022

Great Robotics, a Beijing-based medical robotics company, has reportedly raised close to RMB 100 million...

Company Deals

Visum Pharma Series B+ Financing to Advance R&D and GMP Workshop Construction

Fineline Cube Jun 30, 2022

Visum Pharmaceutical Co., Ltd reportedly raised close to RMB 100 million (USD 14.9 million) in...

Company Deals

Yunnan Jianzhijia Plans Acquisition of Hebei Tangren Pharmacy in USD 309 Million Deal

Fineline Cube Jun 30, 2022

China-based Yunnan Jianzhijia Health-Chain Co, Ltd (SHA: 605266) plans to acquire 100% of compatriot firm...

Policy / Regulatory

Sun Pharma Loses VBP Bid for Bicalutamide in China Due to Quality Failures

Fineline Cube Jun 30, 2022

The Shanghai Medical Products Administration (SMPA) has revoked the winning bid of India-based Sun Pharmaceutical...

Company Drug

Allist Pharmaceuticals’ Furmonertinib Receives NMPA Approval for First-Line NSCLC Treatment

Fineline Cube Jun 30, 2022

Shanghai-based Allist Pharmaceuticals Inc. (SHA: 688578) announced that it has received another indication approval from...

Company Deals

Dakang Medical Secures RMB 400M in Series E Round for Hemodialysis Center Expansion

Fineline Cube Jun 30, 2022

Dakang Medical (DiaCare Medical), a Beijing-based provider of blood purification chain medical services, has reportedly...

Company Drug

Ascentage Pharma’s APG-5918 Receives FDA Approval for First-in-Human Study

Fineline Cube Jun 30, 2022

Suzhou-based Ascentage Pharma (HKG: 6855) announced that it has received approval from the US Food...

Company Deals

Luzhu Bio Files for Hong Kong IPO After RMB 4.42 Billion Valuation

Fineline Cube Jun 30, 2022

Beijing Luzhu Biotechnology Co., Ltd, a leading developer of human vaccines and therapeutic biologics, has...

Company Deals

Youwe Bio’s Series B Financing to Advance Microneedle Technology Commercialization

Fineline Cube Jun 30, 2022

China-based Youwe (Zhuhai) Biotechnology Co., Ltd, a developer of soluble microneedle transdermal drug delivery technology,...

Policy / Regulatory

NHSA Updates NRDL with Focus on Expert Review and Simplified Renewals

Fineline Cube Jun 30, 2022

The National Healthcare Security Administration (NHSA) has released the “2022 National Reimbursement Drug List (NRDL)...

Company Drug

Ascletis Pharma Doses First Patient in China’s Phase II Trial for HIV-1 Treatment with ASC22

Fineline Cube Jun 29, 2022

China-based Ascletis Pharma Inc. (HKG: 1672) announced the dosing of the first patient in its...

Company Drug

Jixing Pharmaceuticals’ Aficamten Receives CDE Approval for Phase III HCM Study

Fineline Cube Jun 29, 2022

China-based Ji Xing Pharmaceuticals announced receiving approval from the Center for Drug Evaluation (CDE) to...

Company Drug

BDgene Advances CRISPR-Based BD111 for Herpes Keratitis with IND Filing

Fineline Cube Jun 29, 2022

Shanghai BDgene Technology Co., Ltd has completed efficacy and preliminary safety studies for BD111, its...

Company Deals

MicroPort NeuroTech Lists in Hong Kong with $43.3 Million IPO

Fineline Cube Jun 29, 2022

MicroPort NeuroTech Limited has successfully completed its initial public offering (IPO) on the Hong Kong...

Company Drug

Bayer’s Kerendia Approved by China’s NMPA for Diabetic Kidney Disease

Fineline Cube Jun 29, 2022

The National Medical Products Administration (NMPA) has approved Bayer’s (ETR: BAYN) Category 1 drug Kerendia...

Company Drug

Hengrui Medicine’s SHR3680 Approved for High Burden Metastatic Prostate Cancer

Fineline Cube Jun 29, 2022

China’s Hengrui Medicine Co., Ltd. (SHA: 600276) announced that its Category 1 drug SHR3680 has...

Company Deals R&D

Legend Biotech Collaborates with Trinity College Dublin on CAR-T Therapies for Solid Tumors

Fineline Cube Jun 29, 2022

China-based Legend Biotech Corporation (NASDAQ: LEGN) has formed a partnership with Trinity College Dublin and...

Company Deals

AnchorDx and West China Hospital Collaborate on Lung Cancer Early Diagnosis

Fineline Cube Jun 29, 2022

Guangzhou-based AnchorDx and West China Hospital of Sichuan University have entered into a transfer agreement...

Posts pagination

1 … 624 625 626 … 634

Recent updates

  • Kintor Pharmaceutical Partners with Fonow Medicine – KT-939 Cosmetic Collaboration Targets China Whitening and Melasma Market
  • Sino Biopharm’s TQB3454 Hits Phase III Endpoints in IDH1+ Biliary Tract Cancer – China’s First IDH1 Inhibitor Poised for NDA Filing
  • CMS Launches Opzelura Nationwide – First Topical JAK Inhibitor for Vitiligo Reaches 1,300+ Pharmacies Across 30 Chinese Provinces
  • Essight Bio’s ES502 Wins FDA Phase I Approval – First TCR×CD3 Bispecific Targeting RAS G12V Mutations Enters Clinic
  • APC Group and Youcare Pharmaceutical Forge Strategic Partnership – Global Distribution Alliance Targets China-India Pharma Collaboratio
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Kintor Pharmaceutical Partners with Fonow Medicine – KT-939 Cosmetic Collaboration Targets China Whitening and Melasma Market

Company Drug

Sino Biopharm’s TQB3454 Hits Phase III Endpoints in IDH1+ Biliary Tract Cancer – China’s First IDH1 Inhibitor Poised for NDA Filing

Company Drug

CMS Launches Opzelura Nationwide – First Topical JAK Inhibitor for Vitiligo Reaches 1,300+ Pharmacies Across 30 Chinese Provinces

Company Drug

Essight Bio’s ES502 Wins FDA Phase I Approval – First TCR×CD3 Bispecific Targeting RAS G12V Mutations Enters Clinic

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.